Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Frequently asked questions
What sector does Fennec Pharmaceuticals Inc (FRX) operate in?
Fennec Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Fennec Pharmaceuticals Inc (FRX) current stock price?
As of the latest data, Fennec Pharmaceuticals Inc stock price is CA$15.00, with a previous close of CA$15.08. Fennec Pharmaceuticals Inc lost -CA$0.08 in the last trading session, representing a -0.53% loss.
What is Fennec Pharmaceuticals Inc (FRX) current market capitalization?
Fennec Pharmaceuticals Inc market cap is approximately 526.01 million.
What is Fennec Pharmaceuticals Inc (FRX) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.17, and the forward EPS is CA$1.32.
What is Fennec Pharmaceuticals Inc (FRX) EBITDA?
Fennec Pharmaceuticals Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.50 million.
Does Fennec Pharmaceuticals Inc (FRX) pay dividends?
No. Fennec Pharmaceuticals Inc does not pay a dividend.
How did Fennec Pharmaceuticals Inc (FRX) perform in its most recent earnings report?
In the last report (June 30, 2026), Fennec Pharmaceuticals Inc posted an EPS surprise of 133.33% and a revenue surprise of 57.36%.
When is Fennec Pharmaceuticals Inc (FRX) next earnings report?
Fennec Pharmaceuticals Inc is expected to release its next earnings report on September 30, 2026.
What is Fennec Pharmaceuticals Inc (FRX) beta (volatility) score?
Fennec Pharmaceuticals Inc has a beta of 1.100, meaning its volatility is roughly in line with the market.
